Current treatment of choice for chronic hepatitis C infection

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.

Original languageEnglish (US)
Pages (from-to)11-18
Number of pages8
JournalInfection and Drug Resistance
Volume4
Issue number1
DOIs
StatePublished - Mar 21 2011

Fingerprint

Chronic Hepatitis C
Infection
Ribavirin
Hepatitis C
Protease Inhibitors
Interferons
Chronic Disease
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology

Cite this

@article{18d9f252f8ac4a7f8c780d57711c2dd7,
title = "Current treatment of choice for chronic hepatitis C infection",
abstract = "More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.",
author = "Tareq Yasin and Riley, {Thomas R.} and Schreibman, {Ian R.}",
year = "2011",
month = "3",
day = "21",
doi = "10.2147/IDR.S4827",
language = "English (US)",
volume = "4",
pages = "11--18",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

Current treatment of choice for chronic hepatitis C infection. / Yasin, Tareq; Riley, Thomas R.; Schreibman, Ian R.

In: Infection and Drug Resistance, Vol. 4, No. 1, 21.03.2011, p. 11-18.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current treatment of choice for chronic hepatitis C infection

AU - Yasin, Tareq

AU - Riley, Thomas R.

AU - Schreibman, Ian R.

PY - 2011/3/21

Y1 - 2011/3/21

N2 - More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.

AB - More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.

UR - http://www.scopus.com/inward/record.url?scp=79952675081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952675081&partnerID=8YFLogxK

U2 - 10.2147/IDR.S4827

DO - 10.2147/IDR.S4827

M3 - Review article

C2 - 21694905

AN - SCOPUS:79952675081

VL - 4

SP - 11

EP - 18

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

IS - 1

ER -